Your browser doesn't support javascript.
loading
A clinically relevant sheep model of orthotopic heart transplantation 24 h after donor brainstem death.
See Hoe, Louise E; Wildi, Karin; Obonyo, Nchafatso G; Bartnikowski, Nicole; McDonald, Charles; Sato, Kei; Heinsar, Silver; Engkilde-Pedersen, Sanne; Diab, Sara; Passmore, Margaret R; Wells, Matthew A; Boon, Ai-Ching; Esguerra, Arlanna; Platts, David G; James, Lynnette; Bouquet, Mahe; Hyslop, Kieran; Shuker, Tristan; Ainola, Carmen; Colombo, Sebastiano M; Wilson, Emily S; Millar, Jonathan E; Malfertheiner, Maximillian V; Reid, Janice D; O'Neill, Hollier; Livingstone, Samantha; Abbate, Gabriella; Sato, Noriko; He, Ting; von Bahr, Viktor; Rozencwajg, Sacha; Byrne, Liam; Pimenta, Leticia P; Marshall, Lachlan; Nair, Lawrie; Tung, John-Paul; Chan, Jonathan; Haqqani, Haris; Molenaar, Peter; Li Bassi, Gianluigi; Suen, Jacky Y; McGiffin, David C; Fraser, John F.
Afiliação
  • See Hoe LE; Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD, Australia. l.seehoe@uq.edu.au.
  • Wildi K; Prince Charles Hospital Northside Clinical Unit, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia. l.seehoe@uq.edu.au.
  • Obonyo NG; School of Pharmacy and Medical Sciences, Griffith University, Southport, QLD, Australia. l.seehoe@uq.edu.au.
  • Bartnikowski N; Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD, Australia.
  • McDonald C; Prince Charles Hospital Northside Clinical Unit, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
  • Sato K; Cardiovascular Research Institute Basel, Basel, Switzerland.
  • Heinsar S; Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD, Australia.
  • Engkilde-Pedersen S; Prince Charles Hospital Northside Clinical Unit, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
  • Diab S; Wellcome Trust Centre for Global Health Research, Imperial College London, London, UK.
  • Passmore MR; Initiative to Develop African Research Leaders (IDeAL), Kilifi, Kenya.
  • Wells MA; Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD, Australia.
  • Boon AC; School of Mechanical, Medical and Process Engineering, Faculty of Engineering, Queensland University of Technology, Brisbane, QLD, Australia.
  • Esguerra A; Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD, Australia.
  • Platts DG; Department of Anaesthesia and Perfusion, The Prince Charles Hospital, Chermside, QLD, Australia.
  • James L; Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD, Australia.
  • Bouquet M; Prince Charles Hospital Northside Clinical Unit, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
  • Hyslop K; Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD, Australia.
  • Shuker T; Prince Charles Hospital Northside Clinical Unit, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
  • Ainola C; Second Department of Intensive Care, North Estonia Medical Centre, Tallinn, Estonia.
  • Colombo SM; Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD, Australia.
  • Wilson ES; Research and Development, Australian Red Cross Lifeblood, Brisbane, QLD, Australia.
  • Millar JE; Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD, Australia.
  • Malfertheiner MV; Prince Charles Hospital Northside Clinical Unit, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
  • Reid JD; Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD, Australia.
  • O'Neill H; Prince Charles Hospital Northside Clinical Unit, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
  • Livingstone S; Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD, Australia.
  • Abbate G; School of Pharmacy and Medical Sciences, Griffith University, Southport, QLD, Australia.
  • Sato N; Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD, Australia.
  • He T; Prince Charles Hospital Northside Clinical Unit, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
  • von Bahr V; Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD, Australia.
  • Rozencwajg S; Research and Development, Australian Red Cross Lifeblood, Brisbane, QLD, Australia.
  • Byrne L; Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD, Australia.
  • Pimenta LP; Prince Charles Hospital Northside Clinical Unit, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
  • Marshall L; Department of Cardiac Surgery, Princess Alexandra Hospital, Brisbane, QLD, Australia.
  • Nair L; Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD, Australia.
  • Tung JP; Prince Charles Hospital Northside Clinical Unit, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
  • Chan J; Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD, Australia.
  • Haqqani H; Prince Charles Hospital Northside Clinical Unit, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
  • Molenaar P; Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD, Australia.
  • Li Bassi G; School of Biomedical Sciences, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
  • Suen JY; Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD, Australia.
  • McGiffin DC; Prince Charles Hospital Northside Clinical Unit, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
  • Fraser JF; Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD, Australia.
Intensive Care Med Exp ; 9(1): 60, 2021 Dec 24.
Article em En | MEDLINE | ID: mdl-34950993
ABSTRACT

BACKGROUND:

Heart transplantation (HTx) from brainstem dead (BSD) donors is the gold-standard therapy for severe/end-stage cardiac disease, but is limited by a global donor heart shortage. Consequently, innovative solutions to increase donor heart availability and utilisation are rapidly expanding. Clinically relevant preclinical models are essential for evaluating interventions for human translation, yet few exist that accurately mimic all key HTx components, incorporating injuries beginning in the donor, through to the recipient. To enable future assessment of novel perfusion technologies in our research program, we thus aimed to develop a clinically relevant sheep model of HTx following 24 h of donor BSD.

METHODS:

BSD donors (vs. sham neurological injury, 4/group) were hemodynamically supported and monitored for 24 h, followed by heart preservation with cold static storage. Bicaval orthotopic HTx was performed in matched recipients, who were weaned from cardiopulmonary bypass (CPB), and monitored for 6 h. Donor and recipient blood were assayed for inflammatory and cardiac injury markers, and cardiac function was assessed using echocardiography. Repeated measurements between the two different groups during the study observation period were assessed by mixed ANOVA for repeated measures.

RESULTS:

Brainstem death caused an immediate catecholaminergic hemodynamic response (mean arterial pressure, p = 0.09), systemic inflammation (IL-6 - p = 0.025, IL-8 - p = 0.002) and cardiac injury (cardiac troponin I, p = 0.048), requiring vasopressor support (vasopressor dependency index, VDI, p = 0.023), with normalisation of biomarkers and physiology over 24 h. All hearts were weaned from CPB and monitored for 6 h post-HTx, except one (sham) recipient that died 2 h post-HTx. Hemodynamic (VDI - p = 0.592, heart rate - p = 0.747) and metabolic (blood lactate, p = 0.546) parameters post-HTx were comparable between groups, despite the observed physiological perturbations that occurred during donor BSD. All p values denote interaction among groups and time in the ANOVA for repeated measures.

CONCLUSIONS:

We have successfully developed an ovine HTx model following 24 h of donor BSD. After 6 h of critical care management post-HTx, there were no differences between groups, despite evident hemodynamic perturbations, systemic inflammation, and cardiac injury observed during donor BSD. This preclinical model provides a platform for critical assessment of injury development pre- and post-HTx, and novel therapeutic evaluation.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Intensive Care Med Exp Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Intensive Care Med Exp Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Austrália